ASSESSMENT OF OVARIAN CANCER BY PET USING F-18-FDG

使用 F-18-FDG 通过 PET 评估卵巢癌

• 批准号: 3203386
• 负责人: KARL F HUBNER
• 金额: $ 18万
• 依托单位: UNIVERSITY OF TENNESSEE KNOXVILLE
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-09-30 至 1996-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3203386
• 关键词: diagnosis design /evaluation; diagnosis quality /standard; evaluation /testing; female reproductive system disorder diagnosis; fluorine; histology; human subject; magnetic resonance imaging; metastasis; neoplasm /cancer classification /staging; neoplasm /cancer relapse /recurrence; noninvasive diagnosis; ovary neoplasms; positron emission tomography; radionuclide diagnosis; radionuclide imaging /scanning; whole body radionuclide scanning

Positron Emission Tomography (PET) using F-18-FDG offers the opportunity to assess the extent of ovarian cancer throughout the abdominopelvic cavity for initial staging, and should be most useful as a routine follow-up test for possible recurrent tumor. Dynamic F-18-FDG PET studies were done in 20 patients at the time of initial diagnosis and staging or when recurrent tumor was suspected. Pet results were compared to Computed Tomography (CT) and surgical findings. Those preliminary data suggest for PET a 91% sensitivity, 75 % specificity and a positive predictive accuracy of 86%; for CT, sensitivity and specificity were 83.03% and 50% respectively. The data also indicate that dynamic data acquisition and time activity curve analysis enhance the diagnostic potential of F-18-FDG PET studies of the pelvis and abdomen. The long-term objective of this project is to validate the sensitivity and accuracy of F-18-FDG in localizing 1 ovarian cancer and metastatic abdominopelvic tumor activity for initial staging, monitoring of treatment, detection of recurrent tumor and guided biopsies. Specific aims are: (1) to further substantiate the high predictive accuracy of F- 18-FDG PET; (20 to determine the limitations of spatial resolution of the technique; (3) to correlate dynamic metabolic PET information with tumor nuclear grade and DNA flow cytometry proliferation indices; (40 to develop a method of parametrically imaging the slopes (accumulation rates) of the FDG uptake curves rather than the summation of accumulated activity (counts/pixel/sec), and (50 to determine whether F-18-FDG PET could assist in evaluating treatment response. Patients with suspected ovarian cancer will be selected for this study. They will have a complete workup for ovarian cancer according to a standard ACS guidelines. Dynamic F-18-FDG PET scans of the pelvis and abdomen and static "whole body' scans of the torso will be done prior to biopsy/hysterectomy, in mid-cycle of chemo- and/or radiation therapy, and at time of suspected recurrent tumor. CT and MRI scans will be obtained concomitantly. PET data analysis will include calculation of standardized uptake values (SUVs), time activity curve (TAC) and graphic Patlak analysis. Each patient will be treated by appropriate measures, including biopsy and/or surgery, combined with radiation therapy or chemotherapy. Tumor recurrence (proven by biopsy/histology) and patient survival are the standard against which the predictive value of F-18-FDG PET and flow cytometry will be measured.

使用F-18-FDG的正电子发射断层扫描（PET）提供了机会 评估卵巢癌在整个腹盆的范围， 腔的初始分期，并应最有用的例行 对可能复发的肿瘤进行随访检查。 动态F-18-FDG PET 在20名患者中进行了初步诊断， 分期或怀疑肿瘤复发时。 比较PET结果 计算机断层扫描（CT）和手术结果。 这些初步 数据表明PET的敏感性为91%，特异性为75%，阳性 预测准确率为86%;对于CT，敏感性和特异性分别为 83.03%和50%。 数据还表明，动态数据 采集和时间活动曲线分析增强了诊断 骨盆和腹部F-18-FDG PET研究的潜力。 本项目的长期目标是验证灵敏度 F-18-FDG对1例卵巢癌及转移灶的定位和准确性 腹盆肿瘤活动性的初步分期，监测 治疗、复发肿瘤检测和引导活检。 具体 目的是：（1）进一步证实F- 18-FDG PET;（20）确定空间分辨率的限制 技术;（3）将动态代谢PET信息与肿瘤相关联 核分级和DNA流式细胞术增殖指数;（40至 开发一种方法的参数成像的斜率（积累 的FDG摄取曲线，而不是累积的总和 活性（计数/像素/秒），和（50）以确定F-18-FDG PET是否 可以帮助评估治疗反应。 本研究将选择疑似卵巢癌患者。 他们将有一个完整的检查卵巢癌根据一个 标准ACS指南。 动态F-18-FDG PET扫描骨盆和 腹部和躯干的静态“全身”扫描将在 活检/子宫切除术，在化疗和/或放疗周期中期，和 在怀疑肿瘤复发时。 将进行CT和MRI扫描 伴随着。 PET数据分析将包括计算 标准化摄取值（SUV）、时间活性曲线（TAC）和图形 Patlak分析。 每位患者将接受适当的治疗，包括活检 和/或手术，结合放射疗法或化学疗法。 肿瘤 复发（经活检/组织学证实）和患者生存率是 F-18-FDG PET和血流的预测值 将测量细胞计数。